ChemoCentryx Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ChemoCentryx stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCXI, but not buy additional shares or sell existing shares.
View analyst ratings for ChemoCentryx or view top-rated stocks.

Wall Street analysts have given ChemoCentryx a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ChemoCentryx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ChemoCentryx saw a increase in short interest in May. As of May 28th, there was short interest totaling 3,140,000 shares, an increase of 35.9% from the May 13th total of 2,310,000 shares. Based on an average daily volume of 2,650,000 shares, the short-interest ratio is currently 1.2 days. Currently, 5.9% of the company's shares are sold short.
View ChemoCentryx's Short Interest.

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for ChemoCentryx.

ChemoCentryx, Inc. (NASDAQ:CCXI) announced its quarterly earnings results on Thursday, April, 29th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.03. The biopharmaceutical company had revenue of $10.35 million for the quarter, compared to analyst estimates of $8.69 million. ChemoCentryx had a negative net margin of 91.54% and a negative trailing twelve-month return on equity of 16.12%.
View ChemoCentryx's earnings history.

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CCXI stock has decreased by 68.9% and is now trading at $12.90.
View which stocks have been most impacted by COVID-19.

8 analysts have issued 12-month price targets for ChemoCentryx's stock. Their forecasts range from $17.00 to $70.00. On average, they expect ChemoCentryx's share price to reach $33.43 in the next twelve months. This suggests a possible upside of 159.1% from the stock's current price.
View analysts' price targets for ChemoCentryx or view top-rated stocks among Wall Street analysts.

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of CCXI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.13%), RA Capital Management L.P. (5.10%), TimesSquare Capital Management LLC (2.22%), Wasatch Advisors Inc. (1.56%), Geode Capital Management LLC (1.22%) and Cormorant Asset Management LP (1.22%). Company insiders that own ChemoCentryx stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends for ChemoCentryx.

CCXI stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., D. E. Shaw & Co. Inc., Cormorant Asset Management LP, Emerald Advisers LLC, Dimensional Fund Advisors LP, Emerald Mutual Fund Advisers Trust, Octagon Capital Advisors LP, and UBS Group AG. Company insiders that have sold ChemoCentryx company stock in the last year include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Thomas A Edwards, and Thomas J Schall.
View insider buying and selling activity for ChemoCentryx or view top insider-selling stocks.

CCXI stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Morgan Stanley, Nuveen Asset Management LLC, BlackRock Inc., Polar Capital Holdings Plc, Citigroup Inc., Barclays PLC, and Lord Abbett & CO. LLC.
View insider buying and selling activity for ChemoCentryx or or view top insider-buying stocks.

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CCXI stock can currently be purchased for approximately $12.90.

ChemoCentryx has a market capitalization of $899.78 million and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55,360,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

ChemoCentryx employs 133 workers across the globe.

The official website for ChemoCentryx is www.chemocentryx.com.

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]